Sigmon, K.N.

patient trial lotrafiban robert swets subs service disease aspirin death /iiia end point group mortality cerebrovascular disease circulation david platelet lotrafiban group stroke point placebo event cerebrovascular william glycoprotein hazard infarction study table michael placebo group 162 mg /d martin pierre heart ischemic creatinine clearance service randomized antagonist assoc safety monitoring board 325 mg /d downloaded february stephen 50 mg bid topol circ.ahajournals.org ischemic attack jeffrey figure complication dougla university maria thoma receptor fatality christopher inhibition ratio clearance cleveland clinic foundation aspirin dose revascularization syndrome creatinine dosing agent iib /iiia antagonist hospital 30 mg michael j pierre theroux richard canada bravo 9190 patients investigator body mass index